These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 24530743)

  • 21. The cellular immune response to Bordetella pertussis in two children with whooping cough.
    Hafler JP; Pohl-Koppe A
    Eur J Med Res; 1998 Nov; 3(11):523-6. PubMed ID: 9810032
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum reactome induced by Bordetella pertussis infection and Pertussis vaccines: qualitative differences in serum antibody recognition patterns revealed by peptide microarray analysis.
    Valentini D; Ferrara G; Advani R; Hallander HO; Maeurer MJ
    BMC Immunol; 2015 Jul; 16():40. PubMed ID: 26129684
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibodies recognizing protective pertussis toxin epitopes are preferentially elicited by natural infection versus acellular immunization.
    Sutherland JN; Chang C; Yoder SM; Rock MT; Maynard JA
    Clin Vaccine Immunol; 2011 Jun; 18(6):954-62. PubMed ID: 21508166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Construction and evaluation of Bordetella pertussis live attenuated vaccine strain BPZE1 producing Fim3.
    Debrie AS; Coutte L; Raze D; Mooi F; Alexander F; Gorringe A; Mielcarek N; Locht C
    Vaccine; 2018 Mar; 36(11):1345-1352. PubMed ID: 29433898
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody response patterns to Bordetella pertussis antigens in vaccinated (primed) and unvaccinated (unprimed) young children with pertussis.
    Cherry JD; Heininger U; Richards DM; Storsaeter J; Gustafsson L; Ljungman M; Hallander HO
    Clin Vaccine Immunol; 2010 May; 17(5):741-7. PubMed ID: 20335431
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increasing FIM2/3 antigen-content improves efficacy of Bordetella pertussis vaccines in mice in vivo without altering vaccine-induced human reactogenicity biomarkers in vitro.
    Queenan AM; Dowling DJ; Cheng WK; Faé K; Fernandez J; Flynn PJ; Joshi S; Brightman SE; Ramirez J; Serroyen J; Wiertsema S; Fortanier A; van den Dobbelsteen G; Levy O; Poolman J
    Vaccine; 2019 Jan; 37(1):80-89. PubMed ID: 30478007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pertussis vaccine: a critique.
    Robbins JB; Schneerson R; Keith JM; Miller MA; Kubler-Kielb J; Trollfors B
    Pediatr Infect Dis J; 2009 Mar; 28(3):237-41. PubMed ID: 19165133
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of B. pertussis vaccine antigen gene variants in pertussis resurgence and possible consequences for vaccine development.
    Preston A
    Hum Vaccin Immunother; 2016 May; 12(5):1274-6. PubMed ID: 26889694
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of pertussis toxin encoded by ptx genes from Bordetella bronchiseptica to model the effects of antigenic drift of pertussis toxin on antibody neutralization.
    Hausman SZ; Burns DL
    Infect Immun; 2000 Jun; 68(6):3763-7. PubMed ID: 10816544
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pertussis vaccines: state-of-the-art and future trends.
    Tefon BE; Özcengiz E; Özcengiz G
    Curr Top Med Chem; 2013; 13(20):2581-96. PubMed ID: 24066885
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pulsed-field gel electrophoresis, pertactin, pertussis toxin S1 subunit polymorphisms, and surfaceome analysis of vaccine and clinical Bordetella pertussis strains.
    Bottero D; Gaillard ME; Fingermann M; Weltman G; Fernández J; Sisti F; Graieb A; Roberts R; Rico O; Ríos G; Regueira M; Binsztein N; Hozbor D
    Clin Vaccine Immunol; 2007 Nov; 14(11):1490-8. PubMed ID: 17699837
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Modern strains of Bordetella pertussis: immunobiological properties and vaccine improvement].
    Shinkarev AS; Mertsalova NU; Mazurova IK; Borisova OIu; Zakharova NS; Ozeretskovskaia MN; Zaĭtsev EM; Poddubikov AV; Britsina MV; Bazhanova IG
    Zh Mikrobiol Epidemiol Immunobiol; 2007; (4):20-5. PubMed ID: 17886371
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunodominance in mouse and human CD4+ T-cell responses specific for the Bordetella pertussis virulence factor P.69 pertactin.
    Stenger RM; Poelen MC; Moret EE; Kuipers B; Bruijns SC; Hoogerhout P; Hijnen M; King AJ; Mooi FR; Boog CJ; van Els CA
    Infect Immun; 2009 Feb; 77(2):896-903. PubMed ID: 19015250
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibodies binding diverse pertactin epitopes protect mice from Bordetella pertussis infection.
    Silva RP; DiVenere AM; Amengor D; Maynard JA
    J Biol Chem; 2022 Mar; 298(3):101715. PubMed ID: 35151691
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of different forms of adenylate cyclase toxin of Bordetella pertussis on protection afforded by an acellular pertussis vaccine in a murine model.
    Cheung GY; Xing D; Prior S; Corbel MJ; Parton R; Coote JG
    Infect Immun; 2006 Dec; 74(12):6797-805. PubMed ID: 16982827
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bordetella pertussis and pertactin-deficient clinical isolates: lessons for pertussis vaccines.
    Hegerle N; Guiso N
    Expert Rev Vaccines; 2014 Sep; 13(9):1135-46. PubMed ID: 24953157
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bordetella pertussis proteins dominating the major histocompatibility complex class II-presented epitope repertoire in human monocyte-derived dendritic cells.
    Stenger RM; Meiring HD; Kuipers B; Poelen M; van Gaans-van den Brink JA; Boog CJ; de Jong AP; van Els CA
    Clin Vaccine Immunol; 2014 May; 21(5):641-50. PubMed ID: 24599530
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Type-specific efficacy of acellular pertussis vaccine.
    Aoyama T; Murase Y; Gonda T; Iwata T
    Am J Dis Child; 1988 Jan; 142(1):40-2. PubMed ID: 2893537
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children.
    Pichichero ME; Deloria MA; Rennels MB; Anderson EL; Edwards KM; Decker MD; Englund JA; Steinhoff MC; Deforest A; Meade BD
    Pediatrics; 1997 Nov; 100(5):772-88. PubMed ID: 9346976
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protective effects of in vivo-expressed autotransporters against Bordetella pertussis infection.
    Suzuki K; Shinzawa N; Ishigaki K; Nakamura K; Abe H; Fukui-Miyazaki A; Ikuta K; Horiguchi Y
    Microbiol Immunol; 2017 Sep; 61(9):371-379. PubMed ID: 28752940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.